Compare · CRL vs NOTV
CRL vs NOTV
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and Inotiv Inc. (NOTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and NOTV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $14.62B, about 5244.6x NOTV ($2.8M).
- Over the past year, CRL is up 63.1% and NOTV is down 94.1% - CRL leads by 157.2 points.
- CRL has hit the wire 6 times in the past 4 weeks while NOTV has been quiet.
- CRL has more recent analyst coverage (25 ratings vs 9 for NOTV).
- Company
- Charles River Laboratories International Inc.
- Inotiv Inc.
- Price
- $300.23-2.04%
- $0.08-14.45%
- Market cap
- $14.62B
- $2.8M
- 1M return
- +6.45%
- -72.65%
- 1Y return
- +63.05%
- -94.12%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 9
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Latest CRL
- Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
- Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
- SEC Form 4 filed by Charles River Laboratories International Inc.
- Charles River and Autolomous Partner to Transform Laboratory Execution Systems
- EVP & Chief Financial Officer Coleman Glenn bought $2,974 worth of shares (10 units at $297.43), increasing direct ownership by 0.04% to 27,762 units (SEC Form 4)
- UBS resumed coverage on Charles River with a new price target
- Charles River Laboratories International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
- Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
- Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
Latest NOTV
- SEC Form 15-12G filed by Inotiv Inc.
- SEC Form 8-K15D5 filed by Inotiv Inc.
- SEC Form EFFECT filed by Inotiv Inc.
- SEC Form EFFECT filed by Inotiv Inc.
- SEC Form EFFECT filed by Inotiv Inc.
- Director Brown Nigel disposed of 104,929 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Taylor Beth A. disposed of 139,616 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Strategy Officer Sagartz John E disposed of 729,626 shares, closing all direct ownership in the company (SEC Form 4)
- Director Neff R Matthew disposed of 151,102 shares, closing all direct ownership in the company (SEC Form 4)
- Director Landman David disposed of 216,243 shares, closing all direct ownership in the company (SEC Form 4)